96 related articles for article (PubMed ID: 21942642)
1. Historical milestones in the development of tibolone (Livial®).
Kloosterboer HJ
Climacteric; 2011 Dec; 14(6):609-21. PubMed ID: 21942642
[TBL] [Abstract][Full Text] [Related]
2. Tibolone: the way to beat many a postmenopausal ailments.
Lazovic G; Radivojevic U; Marinkovic J
Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
[TBL] [Abstract][Full Text] [Related]
3. Effects of tibolone on the breast of postmenopausal women.
Wang PH; Cheng MH; Chao HT; Chao KC
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):121-6. PubMed ID: 17638619
[TBL] [Abstract][Full Text] [Related]
4. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day.
Landgren MB; Helmond FA; Engelen S
Maturitas; 2005 Mar; 50(3):222-30. PubMed ID: 15734603
[TBL] [Abstract][Full Text] [Related]
5. Tissue-selectivity: the mechanism of action of tibolone.
Kloosterboer HJ
Maturitas; 2004 Aug; 48 Suppl 1():S30-40. PubMed ID: 15337246
[TBL] [Abstract][Full Text] [Related]
6. The need for tissue selective menopausal agents.
Eden J
Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():22-7. PubMed ID: 16112952
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Diaby V; Perreault S; Lachaine J
Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
Ziaei S; Moghasemi M; Faghihzadeh S
Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
[TBL] [Abstract][Full Text] [Related]
9. Spanish Menopause Society position statement: use of tibolone in postmenopausal women.
Mendoza N; Abad P; Baró F; Cancelo MJ; Llaneza P; Manubens M; Quereda F; Sánchez-Borrego R
Menopause; 2013 Jul; 20(7):754-60. PubMed ID: 23793166
[TBL] [Abstract][Full Text] [Related]
10. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis--8 years follow-up.
Prelevic GM; Markou A; Arnold A; Bartram C; Puzigaca Z; Ginsburg J
Maturitas; 2004 Mar; 47(3):229-34. PubMed ID: 15036493
[TBL] [Abstract][Full Text] [Related]
11. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
12. Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone.
Verheul HA; van Iersel ML; Delbressine LP; Kloosterboer HJ
Drug Metab Dispos; 2007 Jul; 35(7):1105-11. PubMed ID: 17420283
[TBL] [Abstract][Full Text] [Related]
13. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
Reginster JY
J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
[TBL] [Abstract][Full Text] [Related]
14. Tibolone: a unique version of hormone replacement therapy.
Swegle JM; Kelly MW
Ann Pharmacother; 2004 May; 38(5):874-81. PubMed ID: 15026563
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator.
Campisi R; Marengo FD
Cardiovasc Drug Rev; 2007; 25(2):132-45. PubMed ID: 17614936
[TBL] [Abstract][Full Text] [Related]
16. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
Pickar JH; Mirkin S
Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
[TBL] [Abstract][Full Text] [Related]
17. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor.
Ederveen AG; Kloosterboer HJ
J Bone Miner Res; 2001 Sep; 16(9):1651-7. PubMed ID: 11547834
[TBL] [Abstract][Full Text] [Related]
18. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
Kenemans P
Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
[No Abstract] [Full Text] [Related]
19. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
20. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Kenemans P; Speroff L;
Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
